Meet us at the ESPEN Congress in Milan, 7–10 September!

Logo TauroLock Logo TauroPharm

Antimicrobial efficacy

of TauroLock™ lock solutions

  • TauroLock™ has proven effective against a wide range of bacteria and fungi (including MRSA and VRE).
  • TauroLock™ is not an antibiotic – no bacterial resistance has been observed.
  • TauroLock™ prevents the colonisation of catheters at the planktonic level and the development of biofilm within catheters.

TauroLock™ kills bacteria and fungi within two hours – a time frame available between two treatment sessions.

The antimicrobial efficacy of TauroLock™ solutions significantly reduces the infection rate in access systems for oncology, dialysis, and parenteral nutrition.

Studies on antimicrobial efficacy

Study by Torres-Viera et al.

“In vitro, the antimicrobial agent taurolidine inhibited virtually all of the bacteria tested, including vancomycin-resistant enterococci, oxacillin-resistant staphylococci, and Stenotrophomonas maltophilia, at concentrations between 250 and 2,000 mg/ml. Taurolidine was not effective in experimental endocarditis. While it appears unlikely that this antimicrobial would be useful for systemic therapy, its bactericidal activity and the resistance rates found (<10-9) are favorable indicators for its possible development for topical use.”

Study by Hogan et al.

“…The antiseptics ethanol and Taurolock were shown to be most effective at inactivating biofilm; this was evident against all stages of biofilm investigated...“

Study by Solomon et al.

“…TCH reduced the need for thrombolysis compared to TC (hazard ratio, 0.2; 95%CI: 0.06, 0.5; p < 0.001) and was not significantly different from heparin 5000 U⁄ ml (hazard ratio, 1.4; 95%CI: 0.5, 3.9; p = 0.5)…”

Study by Winnicki et al.

“…Thus, use of taurolidine-based catheter lock solutions containing heparin and urokinase significantly reduced complications related to tunneled hemodialysis catheters when compared to four percent citrate solution and was overall more cost-efficient…”

Meta-analysis by Wouters et al.

"…Taurolidine was the most effective CLS formulation in HPN patients for the prevention of CRBSIs. We suggest discussing with patients the benefits and risks when starting taurolidine, especially in patients who are considered to have a higher risk for CRBSIs."

For personal inquiries, feel free to contact us via phone or email.

Our international distributors based in more than 50 countries will answer your requests ASAP.




We'll keep you posted on upcoming events, free download materials, and research insights.